CO5690612A2 - Mimeticuerpos humanos centrales de la region de bisagra, mimeticos de la eritropoyetina, composiciones, metodos y usos - Google Patents
Mimeticuerpos humanos centrales de la region de bisagra, mimeticos de la eritropoyetina, composiciones, metodos y usosInfo
- Publication number
- CO5690612A2 CO5690612A2 CO06038331A CO06038331A CO5690612A2 CO 5690612 A2 CO5690612 A2 CO 5690612A2 CO 06038331 A CO06038331 A CO 06038331A CO 06038331 A CO06038331 A CO 06038331A CO 5690612 A2 CO5690612 A2 CO 5690612A2
- Authority
- CO
- Colombia
- Prior art keywords
- hinge region
- central
- region
- mimetric
- erythropoyetine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Physics & Mathematics (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
Abstract
1.- Al menos un ácido nucleico de un mimeticuerpo central de la región de bisagra, mimético de la EPO, que comprende al menos un polinucleótido que codifica al menos una secuencia de aminoácidos de las SEQ ID NOS: 82 y 84, o un polinucleótido complementario del mismo.4.- Al menos un ácido nucleico de un mimeticuerpo central de la región de bisagra, mimético de la EPO, que comprende al menos un polinucleótido que codifica un polipéptido de acuerdo con la Fórmula (I): ((V(m)-P(n)-L(o)-H(p)-CH2(q)-CH3(r))(s), en donde V es al menos una porción de un término N de una región variable de inmunoglobulina, P es al menos un péptido mimético de la EPO bioactivo, L es una secuencia enlazante, H es al menos una porción de una región variable central de la bisagra de inmunoglobulina, CH2 es al menos una porción de una región constante CH2 de inmunoglobulina, CH3 es al menos una porción de una región constante CH3 de inmunoglobulina, m, n, o, p, q, r y s pueden ser de manera independiente un entero entre 0, 1 ó 2 y 10.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50734903P | 2003-09-30 | 2003-09-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5690612A2 true CO5690612A2 (es) | 2006-10-31 |
Family
ID=34421611
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO06038331A CO5690612A2 (es) | 2003-09-30 | 2006-04-24 | Mimeticuerpos humanos centrales de la region de bisagra, mimeticos de la eritropoyetina, composiciones, metodos y usos |
Country Status (29)
Country | Link |
---|---|
EP (2) | EP1675579B1 (es) |
JP (1) | JP4810428B2 (es) |
KR (1) | KR101201339B1 (es) |
CN (1) | CN1894275B (es) |
AR (1) | AR046415A1 (es) |
AT (1) | ATE439370T1 (es) |
AU (1) | AU2004277884B2 (es) |
BR (1) | BRPI0414893A (es) |
CA (1) | CA2540665A1 (es) |
CO (1) | CO5690612A2 (es) |
CR (1) | CR8320A (es) |
CY (1) | CY1109579T1 (es) |
DE (1) | DE602004022571D1 (es) |
DK (1) | DK1675579T3 (es) |
EA (1) | EA009377B1 (es) |
EC (1) | ECSP066466A (es) |
ES (1) | ES2329799T3 (es) |
HK (1) | HK1091413A1 (es) |
IL (2) | IL174676A (es) |
NO (1) | NO20061931L (es) |
NZ (1) | NZ546287A (es) |
PL (1) | PL1675579T3 (es) |
PT (1) | PT1675579E (es) |
SG (1) | SG149074A1 (es) |
SI (1) | SI1675579T1 (es) |
TW (1) | TWI344987B (es) |
UA (1) | UA89481C2 (es) |
WO (1) | WO2005032460A2 (es) |
ZA (1) | ZA200603425B (es) |
Families Citing this family (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1799700A4 (en) | 2004-09-27 | 2009-02-11 | Centocor Inc | SRAGE MIMETIC BODIES, COMPOSITIONS, PROCESSES AND USES |
US7910101B2 (en) * | 2004-10-25 | 2011-03-22 | Centocor, Inc. | Melanocortin receptor binding mimetibodies, compositions, methods and uses |
WO2007115148A2 (en) * | 2006-03-31 | 2007-10-11 | Centocor, Inc. | Human mimetic epo hinge core mimetibodies |
WO2008079982A2 (en) | 2006-12-21 | 2008-07-03 | Centocor, Inc. | Liposome composition for targeting egfr receptor |
US8278415B2 (en) | 2006-12-21 | 2012-10-02 | Centocor, Inc. | Dimeric high affinity EGFR constructs and uses thereof |
KR100888022B1 (ko) * | 2006-12-21 | 2009-03-09 | 재단법인 목암생명공학연구소 | 면역글로불린 Fc와 인간 아포리포단백질(a)크링글절편의 융합단백질 LK8Fc |
WO2008079973A2 (en) | 2006-12-21 | 2008-07-03 | Centocor, Inc. | Egfr binding peptides and uses thereof |
ES2750254T3 (es) | 2007-09-27 | 2020-03-25 | Amgen Inc | Formulaciones farmacéuticas |
EP3381445B1 (en) | 2007-11-15 | 2023-10-25 | Amgen Inc. | Aqueous formulation of antibody stablised by antioxidants for parenteral administration |
MX2010008096A (es) | 2008-01-25 | 2010-09-22 | Amgen Inc | Anticuerpos de ferroportina y metodos de uso. |
EP2620448A1 (en) | 2008-05-01 | 2013-07-31 | Amgen Inc. | Anti-hepcidin antibodies and methods of use |
JP6018753B2 (ja) | 2008-11-13 | 2016-11-02 | ザ・ジェネラル・ホスピタル・コーポレイションThe General Hospital Corporation | Bmp−6の調節によって鉄の恒常性を制御するための方法および組成物 |
CN102428105B (zh) | 2009-02-24 | 2015-09-30 | 阿雷克森制药公司 | 含有治疗性tpo/epo模拟肽的抗体 |
JP5809057B2 (ja) * | 2009-09-15 | 2015-11-10 | 株式会社カネカ | 水溶性長鎖分子を付加した修飾エリスロポエチン |
AU2010310457B2 (en) | 2009-10-23 | 2015-07-02 | Amgen Inc. | Vial adapter and system |
AU2010322205B2 (en) | 2009-11-17 | 2015-01-22 | Janssen Biotech, Inc. | Improved bacterial membrane protein secretion |
AU2010322202B2 (en) | 2009-11-17 | 2015-01-22 | Janssen Biotech Inc. | Display of disulfide linked dimeric proteins on filamentous phage |
EP2536435B1 (en) | 2010-02-18 | 2017-11-15 | Janssen Biotech, Inc. | Monkey homolog of human interferon omega |
EP2558482B1 (en) | 2010-04-16 | 2017-09-27 | Janssen Biotech, Inc. | Engineered plant cysteine proteases and their uses |
SG194370A1 (en) | 2010-06-07 | 2013-11-29 | Amgen Inc | Drug delivery device |
FR2964585B1 (fr) * | 2010-09-15 | 2012-10-05 | Snecma | Procede et machine outil pour l'ajustage du contour d'une piece |
US9480624B2 (en) | 2011-03-31 | 2016-11-01 | Amgen Inc. | Vial adapter and system |
PT2699293T (pt) | 2011-04-20 | 2019-05-21 | Amgen Inc | Aparelho de autoinjeção |
BR112014007029A2 (pt) * | 2011-09-23 | 2017-04-11 | Bluebird Bio Inc | métodos aperfeiçoados de terapia gênica |
AU2012322796B2 (en) | 2011-10-14 | 2017-03-16 | Amgen Inc. | Injector and method of assembly |
US8986704B2 (en) * | 2012-07-06 | 2015-03-24 | Valneva Austria Gmbh | Mutant fragments of OspA and methods and uses relating thereto |
EP3165535B1 (en) * | 2012-08-22 | 2019-05-15 | Mogam Biotechnology Research Institute | Screening and engineering method of super-stable immunoglobulin variable domains and their uses |
JP2015535464A (ja) | 2012-11-21 | 2015-12-14 | アムジエン・インコーポレーテツド | 薬剤送達装置 |
EP2968760B1 (en) | 2013-03-15 | 2024-01-03 | Amgen Inc. | Drug cassette, autoinjector, and autoinjector system |
JP6427552B2 (ja) * | 2013-03-15 | 2018-11-21 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | フラビウイルス中和抗体およびその使用方法 |
WO2014152006A2 (en) | 2013-03-15 | 2014-09-25 | Intrinsic Lifesciences, Llc | Anti-hepcidin antibodies and uses thereof |
TWI639449B (zh) | 2013-03-15 | 2018-11-01 | 美商安美基公司 | 用於注射器之匣盒 |
LT2976117T (lt) | 2013-03-22 | 2021-02-25 | Amgen Inc. | Purkštuvas ir surinkimo būdas |
EP3789064A1 (en) | 2013-10-24 | 2021-03-10 | Amgen, Inc | Injector and method of assembly |
EP3501575B1 (en) | 2013-10-24 | 2021-12-01 | Amgen Inc. | Drug delivery system with temperature-sensitive-control |
MX369195B (es) | 2014-01-09 | 2019-10-31 | Valneva Austria Gmbh | Fragmentos mutantes de ospa y métodos y usos relacionados con estos. |
WO2015119906A1 (en) | 2014-02-05 | 2015-08-13 | Amgen Inc. | Drug delivery system with electromagnetic field generator |
CA2945026C (en) | 2014-05-07 | 2023-10-10 | Amgen Inc. | Autoinjector with shock reducing elements |
CA2948003C (en) | 2014-06-03 | 2023-06-27 | Amgen Inc. | Drug delivery system and method of use |
CA2961917A1 (en) | 2014-09-22 | 2016-03-31 | Intrinsic Lifesciences Llc | Humanized anti-hepcidin antibodies and uses thereof |
MX2021014323A (es) | 2014-10-14 | 2023-02-02 | Amgen Inc | Dispositivo de inyección de fármaco con indicadores visuales y audibles. |
ES2785311T3 (es) | 2014-12-19 | 2020-10-06 | Amgen Inc | Dispositivo de administración de fármacos con botón móvil o campo de interfaz de usuario |
US10799630B2 (en) | 2014-12-19 | 2020-10-13 | Amgen Inc. | Drug delivery device with proximity sensor |
CA2976935C (en) | 2015-02-17 | 2020-03-10 | Amgen Inc. | Drug delivery device with vacuum assisted securement and/or feedback |
EP3261690B1 (en) | 2015-02-27 | 2021-12-15 | Amgen Inc. | Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement |
WO2017039786A1 (en) | 2015-09-02 | 2017-03-09 | Amgen Inc. | Syringe assembly adapter for a syringe |
JP7082568B2 (ja) | 2015-12-09 | 2022-06-08 | アムジエン・インコーポレーテツド | 信号伝達キャップ付き自動注射器 |
US11154661B2 (en) | 2016-01-06 | 2021-10-26 | Amgen Inc. | Auto-injector with signaling electronics |
WO2017160799A1 (en) | 2016-03-15 | 2017-09-21 | Amgen Inc. | Reducing probability of glass breakage in drug delivery devices |
US11541168B2 (en) | 2016-04-29 | 2023-01-03 | Amgen Inc. | Drug delivery device with messaging label |
US11389588B2 (en) | 2016-05-02 | 2022-07-19 | Amgen Inc. | Syringe adapter and guide for filling an on-body injector |
WO2017197222A1 (en) | 2016-05-13 | 2017-11-16 | Amgen Inc. | Vial sleeve assembly |
EP3458988B1 (en) | 2016-05-16 | 2023-10-18 | Amgen Inc. | Data encryption in medical devices with limited computational capability |
EP3465124A1 (en) | 2016-06-03 | 2019-04-10 | Amgen Inc. | Impact testing apparatuses and methods for drug delivery devices |
US11285266B2 (en) | 2016-07-01 | 2022-03-29 | Amgen Inc. | Drug delivery device having minimized risk of component fracture upon impact events |
WO2018034784A1 (en) | 2016-08-17 | 2018-02-22 | Amgen Inc. | Drug delivery device with placement detection |
WO2018081234A1 (en) | 2016-10-25 | 2018-05-03 | Amgen Inc. | On-body injector |
JP2020503976A (ja) | 2017-01-17 | 2020-02-06 | アムジエン・インコーポレーテツド | 注入デバイスならびに関連する使用および組立方法 |
AU2018220538B2 (en) | 2017-02-17 | 2023-12-14 | Amgen Inc. | Drug delivery device with sterile fluid flowpath and related method of assembly |
JP7280189B2 (ja) | 2017-02-17 | 2023-05-23 | アムジエン・インコーポレーテツド | 薬物送達装置用の挿入機構 |
JP2020508803A (ja) | 2017-03-06 | 2020-03-26 | アムジエン・インコーポレーテツド | 作動防止特徴部を備える薬物送達デバイス |
KR102627069B1 (ko) | 2017-03-07 | 2024-01-18 | 암겐 인코포레이티드 | 과압에 의한 바늘 삽입 |
JP2020509837A (ja) | 2017-03-09 | 2020-04-02 | アムジエン・インコーポレーテツド | 薬剤送達装置のための挿入機構 |
EP3570871B1 (en) | 2017-03-20 | 2020-11-18 | H. Hoffnabb-La Roche Ag | Method for in vitro glycoengineering of an erythropoiesis stimulating protein |
LT3600491T (lt) | 2017-03-28 | 2023-10-10 | Amgen Inc. | Stūmoklio koto ir švirkšto konstrukcinė sistema ir būdas |
US11590294B2 (en) | 2017-06-08 | 2023-02-28 | Amgen Inc. | Syringe assembly for a drug delivery device and method of assembly |
MX2019014615A (es) | 2017-06-08 | 2020-02-07 | Amgen Inc | Dispositivo de administracion de farmacos accionado por par de torsion. |
EP3641857A1 (en) | 2017-06-22 | 2020-04-29 | Amgen Inc. | Device activation impact/shock reduction |
EP3641861A1 (en) | 2017-06-23 | 2020-04-29 | Amgen Inc. | Electronic drug delivery device comprising a cap activated by a switch assembly |
JP7408398B2 (ja) | 2017-07-14 | 2024-01-05 | アムジエン・インコーポレーテツド | 二重ねじりばねシステムを有する針挿入後退システム |
IL271173B2 (en) | 2017-07-21 | 2024-04-01 | Amgen Inc | Gas permeable sealing element for drug container and methods of assembly |
JP2020528296A (ja) | 2017-07-25 | 2020-09-24 | アムジエン・インコーポレーテツド | ギヤモジュールを有する薬物送達デバイス及び関連する組立方法 |
WO2019022950A1 (en) | 2017-07-25 | 2019-01-31 | Amgen Inc. | DRUG DELIVERY DEVICE WITH CONTAINER ACCESS SYSTEM AND ASSEMBLY METHOD THEREOF |
EP3664863A2 (en) | 2017-08-09 | 2020-06-17 | Amgen Inc. | Hydraulic-pneumatic pressurized chamber drug delivery system |
EP3668567A1 (en) | 2017-08-18 | 2020-06-24 | Amgen Inc. | Wearable injector with sterile adhesive patch |
US11103636B2 (en) | 2017-08-22 | 2021-08-31 | Amgen Inc. | Needle insertion mechanism for drug delivery device |
EP3691717B1 (en) | 2017-10-04 | 2023-02-08 | Amgen Inc. | Flow adapter for drug delivery device |
EP4257164A3 (en) | 2017-10-06 | 2024-01-17 | Amgen Inc. | Drug delivery device with interlock assembly and related method of assembly |
MA50348A (fr) | 2017-10-09 | 2020-08-19 | Amgen Inc | Dispositif d'administration de médicament comprenant un ensemble d'entraînement et procédé d'assemblage associé |
WO2019090086A1 (en) | 2017-11-03 | 2019-05-09 | Amgen Inc. | Systems and approaches for sterilizing a drug delivery device |
US20200338271A1 (en) | 2017-11-06 | 2020-10-29 | Amgen Inc. | Fill-finish assemblies and related methods |
EP3706830A1 (en) | 2017-11-06 | 2020-09-16 | Amgen Inc. | Drug delivery device with placement and flow sensing |
CN111225696B (zh) | 2017-11-10 | 2023-07-18 | 安进公司 | 用于药物递送装置的柱塞 |
SG11202003004RA (en) | 2017-11-16 | 2020-04-29 | Amgen Inc | Door latch mechanism for drug delivery device |
MX2020005066A (es) | 2017-11-16 | 2020-08-20 | Amgen Inc | Autoinyector con deteccion de detencion y punto final. |
US10835685B2 (en) | 2018-05-30 | 2020-11-17 | Amgen Inc. | Thermal spring release mechanism for a drug delivery device |
US11083840B2 (en) | 2018-06-01 | 2021-08-10 | Amgen Inc. | Modular fluid path assemblies for drug delivery devices |
US20210128844A1 (en) | 2018-07-24 | 2021-05-06 | Amgen Inc. | Delivery devices for administering drugs |
WO2020023336A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with grip portion |
WO2020023444A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Delivery devices for administering drugs |
US20210260279A1 (en) | 2018-07-24 | 2021-08-26 | Amgen Inc. | Hybrid drug delivery devices with optional grip portion and related method of preparation |
CA3103105A1 (en) | 2018-07-31 | 2020-02-06 | Amgen Inc. | Fluid path assembly for a drug delivery device |
AU2019347710A1 (en) | 2018-09-24 | 2021-02-04 | Amgen Inc. | Interventional dosing systems and methods |
EP3856283A1 (en) | 2018-09-28 | 2021-08-04 | Amgen Inc. | Muscle wire escapement activation assembly for a drug delivery device |
WO2020072577A1 (en) | 2018-10-02 | 2020-04-09 | Amgen Inc. | Injection systems for drug delivery with internal force transmission |
MA53818A (fr) | 2018-10-05 | 2022-01-12 | Amgen Inc | Dispositif d'administration de médicament ayant un indicateur de dose |
EP3866889A1 (en) | 2018-10-15 | 2021-08-25 | Amgen Inc. | Platform assembly process for drug delivery device |
EA202191037A1 (ru) | 2018-10-15 | 2021-08-05 | Эмджен Инк. | Устройство доставки лекарственного средства, имеющее демпферный механизм |
TWI831847B (zh) | 2018-11-01 | 2024-02-11 | 美商安進公司 | 部分針頭縮回之藥物遞送裝置及其操作方法 |
MA54048A (fr) | 2018-11-01 | 2022-02-09 | Amgen Inc | Dispositifs d'administration de médicament avec rétraction partielle de l'organe d'administration de médicament |
US20220031939A1 (en) | 2018-11-01 | 2022-02-03 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
AU2020263289A1 (en) | 2019-04-24 | 2021-09-16 | Amgen Inc. | Syringe sterilization verification assemblies and methods |
EP4017560A2 (en) | 2019-08-23 | 2022-06-29 | Amgen, Inc | Drug delivery device with configurable needle shield engagement components and related methods |
AU2022279223A1 (en) | 2021-05-21 | 2023-10-19 | Amgen Inc. | Method of optimizing a filling recipe for a drug container |
WO2024094457A1 (en) | 2022-11-02 | 2024-05-10 | F. Hoffmann-La Roche Ag | Method for producing glycoprotein compositions |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4309989A (en) | 1976-02-09 | 1982-01-12 | The Curators Of The University Of Missouri | Topical application of medication by ultrasound with coupling agent |
FR2374910A1 (fr) | 1976-10-23 | 1978-07-21 | Choay Sa | Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
US5149636A (en) | 1982-03-15 | 1992-09-22 | Trustees Of Columbia University In The City Of New York | Method for introducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
SE448277B (sv) | 1985-04-12 | 1987-02-09 | Draco Ab | Indikeringsanordning vid en doseringsanordning for lekemedel |
US4870163A (en) | 1985-08-29 | 1989-09-26 | New York Blood Center, Inc. | Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
SE453566B (sv) | 1986-03-07 | 1988-02-15 | Draco Ab | Anordning vid pulverinhalatorer |
US4767402A (en) | 1986-07-08 | 1988-08-30 | Massachusetts Institute Of Technology | Ultrasound enhancement of transdermal drug delivery |
US4925673A (en) | 1986-08-18 | 1990-05-15 | Clinical Technologies Associates, Inc. | Delivery systems for pharmacological agents encapsulated with proteinoids |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
DE3631229A1 (de) | 1986-09-13 | 1988-03-24 | Basf Ag | Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung |
EP0832981A1 (en) | 1987-02-17 | 1998-04-01 | Pharming B.V. | DNA sequences to target proteins to the mammary gland for efficient secretion |
EP0288088B1 (en) | 1987-04-24 | 1994-03-09 | Teijin Limited | Detection of tumor necrosis factor; monoclonal antibody and kit |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
US4956288A (en) | 1988-04-22 | 1990-09-11 | Biogen, Inc. | Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5266491A (en) | 1989-03-14 | 1993-11-30 | Mochida Pharmaceutical Co., Ltd. | DNA fragment and expression plasmid containing the DNA fragment |
DK0486526T3 (da) | 1989-08-07 | 1996-06-24 | Peptide Technology Ltd | Bindingsligander for tumornekrosefaktor |
US5580575A (en) | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
GB9022648D0 (en) | 1990-10-18 | 1990-11-28 | Charing Cross Sunley Research | Polypeptide and its use |
US5404871A (en) | 1991-03-05 | 1995-04-11 | Aradigm | Delivery of aerosol medications for inspiration |
EP0575545B1 (en) | 1991-03-15 | 2003-05-21 | Amgen Inc. | Pegylation of polypeptides |
ES2284226T3 (es) | 1991-07-02 | 2007-11-01 | Nektar Therapeutics | Dispositivo para proporcionar medicamentos en aerosol. |
US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
AU4829593A (en) | 1992-09-23 | 1994-04-12 | Fisons Plc | Inhalation device |
ES2127837T3 (es) | 1992-10-19 | 1999-05-01 | Dura Pharma Inc | Inhalador para polvo seco. |
US5643252A (en) | 1992-10-28 | 1997-07-01 | Venisect, Inc. | Laser perforator |
US5849695A (en) | 1993-01-13 | 1998-12-15 | The Regents Of The University Of California | Parathyroid hormone analogues useful for treatment of osteoporosis and disorders of calcium meatabolism in mammals |
DE69414369T2 (de) | 1993-01-19 | 1999-05-27 | Glaxo Group Ltd | Aerosol-spender und verfahren zu seiner herstellung |
EP1978095A1 (en) | 1993-02-12 | 2008-10-08 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptor proteins for controlling signal transduction and ligands binding thereto |
US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
US5814599A (en) | 1995-08-04 | 1998-09-29 | Massachusetts Insitiute Of Technology | Transdermal delivery of encapsulated drugs |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US5786331A (en) | 1994-02-02 | 1998-07-28 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-1 receptor |
US5880096A (en) | 1994-02-02 | 1999-03-09 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-1 receptor |
US5608035A (en) | 1994-02-02 | 1997-03-04 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-1 receptor |
US5767078A (en) | 1995-06-07 | 1998-06-16 | Johnson; Dana L. | Agonist peptide dimers |
AU6163196A (en) * | 1995-06-07 | 1996-12-30 | Smithkline Beecham Corporation | Method for obtaining receptor agonist antibodies |
GB9526100D0 (en) | 1995-12-20 | 1996-02-21 | Intersurgical Ltd | Nebulizer |
CN1213974A (zh) | 1996-01-03 | 1999-04-14 | 葛兰素集团有限公司 | 吸入器具 |
US5879681A (en) | 1997-02-07 | 1999-03-09 | Emisphere Technolgies Inc. | Compounds and compositions for delivering active agents |
US5921447A (en) | 1997-02-13 | 1999-07-13 | Glaxo Wellcome Inc. | Flow-through metered aerosol dispensing apparatus and method of use thereof |
IL120943A (en) | 1997-05-29 | 2004-03-28 | Univ Ben Gurion | A system for administering drugs through the skin |
US6165476A (en) * | 1997-07-10 | 2000-12-26 | Beth Israel Deaconess Medical Center | Fusion proteins with an immunoglobulin hinge region linker |
US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
WO2001083525A2 (en) * | 2000-05-03 | 2001-11-08 | Amgen Inc. | Modified peptides, comprising an fc domain, as therapeutic agents |
US7396917B2 (en) * | 2000-12-05 | 2008-07-08 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies |
DK1642910T3 (da) * | 2000-12-05 | 2012-05-07 | Alexion Pharma Inc | Rationelt designede atistoffer |
US6900292B2 (en) * | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
WO2003084477A2 (en) * | 2002-03-29 | 2003-10-16 | Centocor, Inc. | Mammalian cdr mimetibodies, compositions, methods and uses |
WO2004002417A2 (en) * | 2002-06-28 | 2004-01-08 | Centocor, Inc. | Mammalian ch1 deleted mimetibodies, compositions, methods and uses |
AU2003256336A1 (en) * | 2002-06-28 | 2004-01-19 | Centocor, Inc. | Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses |
-
2004
- 2004-03-09 UA UAA200604029A patent/UA89481C2/uk unknown
- 2004-09-03 PL PL04783275T patent/PL1675579T3/pl unknown
- 2004-09-03 BR BRPI0414893-2A patent/BRPI0414893A/pt not_active IP Right Cessation
- 2004-09-03 AU AU2004277884A patent/AU2004277884B2/en not_active Ceased
- 2004-09-03 AT AT04783275T patent/ATE439370T1/de active
- 2004-09-03 KR KR1020067008486A patent/KR101201339B1/ko not_active IP Right Cessation
- 2004-09-03 WO PCT/US2004/028976 patent/WO2005032460A2/en active Application Filing
- 2004-09-03 CN CN200480035434XA patent/CN1894275B/zh not_active Expired - Fee Related
- 2004-09-03 SG SG200809659-6A patent/SG149074A1/en unknown
- 2004-09-03 ES ES04783275T patent/ES2329799T3/es active Active
- 2004-09-03 CA CA002540665A patent/CA2540665A1/en not_active Abandoned
- 2004-09-03 JP JP2006533891A patent/JP4810428B2/ja not_active Expired - Fee Related
- 2004-09-03 EP EP04783275A patent/EP1675579B1/en active Active
- 2004-09-03 SI SI200431268T patent/SI1675579T1/sl unknown
- 2004-09-03 NZ NZ546287A patent/NZ546287A/en unknown
- 2004-09-03 EA EA200600525A patent/EA009377B1/ru not_active IP Right Cessation
- 2004-09-03 EP EP09075328A patent/EP2123675A3/en not_active Withdrawn
- 2004-09-03 DK DK04783275T patent/DK1675579T3/da active
- 2004-09-03 DE DE602004022571T patent/DE602004022571D1/de active Active
- 2004-09-03 PT PT04783275T patent/PT1675579E/pt unknown
- 2004-09-29 TW TW093129457A patent/TWI344987B/zh not_active IP Right Cessation
- 2004-09-30 AR ARP040103559A patent/AR046415A1/es not_active Application Discontinuation
-
2006
- 2006-03-30 IL IL174676A patent/IL174676A/en not_active IP Right Cessation
- 2006-03-30 EC EC2006006466A patent/ECSP066466A/es unknown
- 2006-03-30 CR CR8320A patent/CR8320A/es not_active Application Discontinuation
- 2006-04-24 CO CO06038331A patent/CO5690612A2/es not_active Application Discontinuation
- 2006-04-28 ZA ZA2006/03425A patent/ZA200603425B/en unknown
- 2006-04-28 NO NO20061931A patent/NO20061931L/no not_active Application Discontinuation
- 2006-11-03 HK HK06112140.8A patent/HK1091413A1/xx not_active IP Right Cessation
-
2009
- 2009-07-28 IL IL200117A patent/IL200117A/en not_active IP Right Cessation
- 2009-11-06 CY CY20091101155T patent/CY1109579T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5690612A2 (es) | Mimeticuerpos humanos centrales de la region de bisagra, mimeticos de la eritropoyetina, composiciones, metodos y usos | |
DE3853328T2 (de) | Subtilisin-analoge. | |
DE69525340T2 (de) | Verbesserungen in zusammensetzungen von kopolymeren enthaltend kopolymer-1 | |
EA199900355A1 (ru) | Теломераза обратная тринскриптаза | |
DK0423302T3 (da) | Anvendelse af hidtil ukendte DNA-fragmenter som kodende sekvens for et signalpeptid til sekretion af modne proteiner i rekombinant gær, ekspressionskassetter, transformeret gær og tilsvarende fremgangsmåde til fremstilling af proteiner | |
DE69029406D1 (en) | Polypeptid | |
CA2161808A1 (en) | Bmp-11 compositions | |
SE9003374D0 (sv) | A collagen binding protein as well as its preparation | |
WO2001045738A3 (en) | Use of heat shock proteins to enhance production of chemokines by a cell | |
SE8801723D0 (sv) | Fibronectin binding protein as well as its preparation | |
SE9602822D0 (sv) | New receptor | |
DK0804182T3 (da) | Anvendelse af gabapentin ved behandling af angst og panik | |
IL162133A0 (en) | Method of increasing protein expression, proteins and polynucleotides | |
WO2001098355A3 (en) | Cgi-69 compositions and methods of use | |
SE9604439D0 (sv) | New receptor | |
WO2004069989A3 (en) | Novel purified phosphodiesterase polypeptides | |
EP0956354A4 (en) | RECOMBINANT N-PROTEINASE, AND PRODUCTION, METHODS AND USES THEREOF | |
WO2000032794A3 (en) | Chlamydia antigens and corresponding dna fragments and uses thereof | |
HUP9903711A2 (hu) | Kemokin-béta-15 | |
ATE193543T1 (de) | Antithrombotische peptide aus den wiederholten sequenzen des typs ii |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Application granted | ||
FD | Application lapsed |